The first study tested the reproducibility of ex vivo ELISpot in areas of natural malaria transmission, where activities were low, and there were fewer positive responses to CSP than to AMA1 when the same Ap and Cp peptide pools described in the current study were used to stimulate subject PBMCs [25]. The gene discussed is DNAJC5; the disease is malaria.